Race Oncology Ltd (ASX:RAC) today announced that Dr David Fuller has resigned as chief medical officer, effective today, to take up the role of CMO at Aucentra Therapeutics.
CEO and managing director Phillip Lynch said: “We’re grateful to David for his strong domain expertise and dedication as we have grown Race.
Strong strategic position
“He has successfully led the Race clinical team in implementing our clinical programs both in Australia and overseas and leaves us in a very strong strategic position. We wish David all the best in his new role with Aucentra Therapeutics.”
Dr David Fuller said: “I have enjoyed the opportunity to work with the Race team progressing the Three Pillar strategy. I wish the company every success as it moves ahead.”
Interim CMO
The company has appointed Dr Ajay Duggal of Adnovate Clinical as interim CMO, who starts on November 14, pending the appointment of a new full-time CMO.
Dr Duggal will work closely with Race’s executive and clinical team, which has been actively involved in all aspects of the design and implementation of Race’s clinical programs.
The company expects all clinical programs to continue without disruption.
The recruitment of a permanent CMO is being undertaken by Coulter Partners, a specialised international pharma/biotech executive recruitment firm which was appointed following a diligent evaluation process by Race.